R&D Systems Inc. Tocris Bioscience Boston Biochem

CL 82198 hydrochloride

Cat. No. 2632

CL 82198 hydrochloride C17H23N2O3.HCl [1188890-36-9]

Price and Availability

For CL 82198 hydrochloride pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: N-[4-(4-Morpholinyl)butyl]-2-benzofurancarboxamide hydrochloride

Biological Activity

Selective inhibitor of MMP-13 (89% inhibition at 10 μg/mL) that displays no activity at MMP-1, MMP-9 or TACE. Inhibits in vitro invasion by the human pituitary adenoma cell line HP75.

Technical Data

M.Wt:
338.83
Formula:
C17H23N2O3.HCl
Solubility:
Soluble to 100 mM in water and to 75 mM in DMSO
Purity:
>98 %
Storage:
Desiccate at RT
CAS No:
1188890-36-9

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Select another batch:
Safety Data Sheet: View Safety Data Sheet

References

Chen et al (2000) Structure-based design of a novel, potent, and selective inhibitor for MMP-13 utilizing NMR spectroscopy and computer-aided molecular design. J.Am.Chem.Soc. 122 9648.

Borg et al (2003) IL1 alpha, IL6 and MMP13 are required for invasion by the human pituitary cell line HP75. Endocrine Abstr. 5 122.

If you know of a relevant citation for this product please let us know.

Keywords: CL 82198 hydrochloride, supplier, Selective, inhibitors, MMP-13, Matrixins, Matrix, Metalloproteinase, MMP, Metalloprotease, Proteinases, Proteases, CL82198, hydrochloride

Quick Order

Find multiple products by catalog number

divider line

Cancer Research Product Guide

Cancer Research Guide

Highlights over 350 products for cancer research. Request a copy or view PDF today.

divider line

VEGF Pathway & Anti-Angiogenic Therapy

Written by N. Ferrara & Y. Crawford

Angiogenesis Poster

A summary of antiangiogenic therapies targeting the VEGF pathway and the mechanisms of therapy resistance.

divider line

New Product Guide

NPG

Highlights 140 new products added in the first half of 2014. Request a copy or view PDF today.

divider line

New Products in this Area

Ramipril

Non-peptide, competitive angiotensin converting enzyme (ACE) inhibitor

Aprotinin

Competitive serine protease inhibitor

TCID

Selective ubiquitin C-terminal hydrolase-L3 (UCH-L3) inhibitor

2-MPPA

Selective glutamate carboxypeptidase II (GCP II) inhibitor; orally bioavailable

E 64

Potent and irreversible cysteine protease inhibitor

AEBSF

Broad spectrum, irreversible inhibitor of serine proteases

TC-E 5006

γ-secretase modulator; reduces Aβ42 levels

PTIQ

Potent MMP-3 expression inhibitor; neuroprotective

Sign-up for new product e-alerts
divider line

Bio-Techne Events

2014 ASCB/IFCB meeting

ASCB/IFCB 2014

December 6 - 10, 2014

Philadelphia, USA

Booth Number: 515